BR0103169A - Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd) - Google Patents
Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd)Info
- Publication number
- BR0103169A BR0103169A BR0103169-4A BR0103169A BR0103169A BR 0103169 A BR0103169 A BR 0103169A BR 0103169 A BR0103169 A BR 0103169A BR 0103169 A BR0103169 A BR 0103169A
- Authority
- BR
- Brazil
- Prior art keywords
- adhd
- treatment
- attention deficit
- pharmaceutical composition
- hyperactivity disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Patente de Invenção: "COMPOSIçãO FARMACêUTICA PARA O TRATAMENTO DO DISTúRBIO DE HIPERATIVIDADE DE DéFICIT DE ATENçãO (ADHD)". São reveladas composições farmacêuticas para o tratamento do distúrbio hiperactivo de déficit de atenção (ADHD). Estão incluídas nas composições farmacêuticas uma combinação terapeuticamente eficaz de um agonista parcial de receptor de nicotina e um agente anti-ADHD e um veículo farmaceuticamente aceitável. Também é revelado o método de utilização destes compostos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22171800P | 2000-07-31 | 2000-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0103169A true BR0103169A (pt) | 2002-05-28 |
Family
ID=22829041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0103169-4A BR0103169A (pt) | 2000-07-31 | 2001-07-31 | Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd) |
Country Status (6)
Country | Link |
---|---|
US (2) | US20020016334A1 (pt) |
EP (1) | EP1177798A3 (pt) |
JP (1) | JP2002316949A (pt) |
BR (1) | BR0103169A (pt) |
CA (1) | CA2354237C (pt) |
IL (1) | IL144506A0 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1321107C (zh) * | 2001-04-20 | 2007-06-13 | 辉瑞产品公司 | 1,3-取代的茚类和芳基稠合的氮杂多环化合物的制备方法 |
AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
WO2003007956A1 (en) | 2001-07-20 | 2003-01-30 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
US20030036555A1 (en) * | 2001-08-03 | 2003-02-20 | Boehringer Ingelheim Pharma Kg | Pramipexole for the treatment of ADHD |
DE10137633A1 (de) * | 2001-08-03 | 2003-02-20 | Boehringer Ingelheim Pharma | Pramipexol zur Behandlung von ADHD |
WO2003029252A1 (en) | 2001-10-02 | 2003-04-10 | Pharmacia & Upjohn Company | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
MXPA04004373A (es) | 2001-11-09 | 2004-08-11 | Upjohn Co | Compuestos heterociclicos condensados con fenilo azabiciclo para el tratamiento de enfermedades. |
WO2003070731A2 (en) * | 2002-02-19 | 2003-08-28 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
EP1476449A1 (en) * | 2002-02-19 | 2004-11-17 | PHARMACIA & UPJOHN COMPANY | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
US20040002500A1 (en) * | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
US20040000689A1 (en) * | 2002-06-28 | 2004-01-01 | Erh-Kun Lai | Dual-bit MONOS/SONOS memory structure with non-continuous floating gate |
JP2006506395A (ja) * | 2002-11-01 | 2006-02-23 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | CNS疾患の治療のための、α7ニコチンアゴニスト活性及び5HT3アンタゴニスト活性を有する化合物 |
EA200500783A1 (ru) * | 2002-12-11 | 2005-12-29 | ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи | Комбинация для лечения синдрома дефицита внимания с гиперактивностью |
WO2004069339A1 (en) * | 2003-01-29 | 2004-08-19 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
US8030300B2 (en) | 2003-06-10 | 2011-10-04 | Georgetown University | Ligands for nicotinic acetylcholine receptors, and methods of making and using them |
EP2258358A3 (en) * | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
WO2008083442A1 (en) * | 2007-01-10 | 2008-07-17 | Brc Operations Pty Limited | Method for formulating combination medications for adhd |
CN103044423B (zh) * | 2012-01-11 | 2013-10-23 | 上海合全药物研发有限公司 | 取代的吡啶-2-酮类化合物及其制备方法 |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神***病を処置するための方法および組成物 |
TWI709417B (zh) * | 2013-10-07 | 2020-11-11 | 美商帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX19222A (es) * | 1989-01-23 | 1993-12-01 | Pfizer | Agentes ansioliticos bis-aza-biciclicos |
US5658590A (en) * | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
EP0937077B1 (en) * | 1996-10-30 | 2006-05-17 | Pfizer Inc. | Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy |
NZ504482A (en) * | 1997-12-31 | 2003-01-31 | Pfizer Prod Inc | Aryl fused azapolycyclic compounds and pharmaceuticals thereof which bind to neuronal nicotinic acetylcholine specific recpetor sites and are useful for modulating cholinergic function |
US6218383B1 (en) * | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
-
2001
- 2001-05-25 US US09/865,793 patent/US20020016334A1/en not_active Abandoned
- 2001-07-23 IL IL14450601A patent/IL144506A0/xx unknown
- 2001-07-27 CA CA002354237A patent/CA2354237C/en not_active Expired - Fee Related
- 2001-07-27 EP EP01306455A patent/EP1177798A3/en not_active Withdrawn
- 2001-07-31 BR BR0103169-4A patent/BR0103169A/pt not_active IP Right Cessation
- 2001-07-31 JP JP2001231554A patent/JP2002316949A/ja active Pending
-
2004
- 2004-05-21 US US10/851,826 patent/US20040220184A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL144506A0 (en) | 2002-05-23 |
EP1177798A2 (en) | 2002-02-06 |
CA2354237C (en) | 2005-05-24 |
EP1177798A3 (en) | 2003-03-05 |
US20040220184A1 (en) | 2004-11-04 |
US20020016334A1 (en) | 2002-02-07 |
CA2354237A1 (en) | 2002-01-31 |
JP2002316949A (ja) | 2002-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0103169A (pt) | Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd) | |
BR9914251A (pt) | Formulações orais de liberação sustentada | |
IT1283102B1 (it) | Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele | |
AP1424A (en) | 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens. | |
BR0109837A (pt) | Composição farmacêutica para o tratamento da dor aguda, crÈnica e/ou neuropática e enxaquecas | |
ID29393A (id) | Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah | |
DE69940769D1 (de) | Orale flüssige zusammensetzungen | |
NO20003721L (no) | Farmasøytisk aktivt morfolinol | |
GT199700009AA (es) | Terapia combinada para la osteoporosis | |
PL372809A1 (en) | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | |
RS49756B (sr) | Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija | |
BR0001515A (pt) | Composições de espuma estáveis | |
BR0110420A (pt) | Agonistas muscarìnicos | |
ATE209207T1 (de) | Androgen rezeptor modulator verbindungen und verfahren | |
HUP0104696A3 (en) | Pharmaceutical composition containing 5ht1 receptor agonists and metoclopramide for the treatment of migraine | |
BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
LU91281I2 (fr) | Preotact-hormone parathyroïde | |
BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
BR0008509A (pt) | Composição farmacêutica oral estabilizada contendo iodeto e iodato e método | |
NO20011695L (no) | Farmasöytisk sammensetning med langvarig frigivelse og fremgangsmåte for å frigi farmasöytisk aktivt middel | |
BR0207872A (pt) | Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração | |
EE200300234A (et) | Bifenüülkarboksamiidühendite kasutamine lipiiditaset alandavate toimeainetena, meetod nende valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
DE69716469D1 (de) | Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol | |
PT1358177E (pt) | Tratamento de desordens afectivas atraves da accao combinada de um agonista do receptor nicotinico e uma substancia manoaminergica | |
HUP0003410A2 (hu) | Azapoliciklusos vegyületeket tartalmazó kombinációs gyógyszerkészítmények emlősök nikotinélvezetének megelőzésére és kezelésére |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009. |